FDA Clears New KEYTRUDA Regimens for Bladder Cancer Care
Rahway, N.J., Nov. 21, 2025 — In a major advancement for oncology treatment, the U.S. Food and Drug Administration...
Prescription, Generic, and Over-The-Counter: Drugs & Products.
Koselugo Secures US Approval, Advancing Targeted NF1 Care
Wilmington, Delaware, November 2025 AstraZeneca has announced that Koselugo (selumetinib) has received expanded FDA approval in the United States...
AbbVie’s Epkinly Gets FDA Nod for Follicular Lymphoma Combo
NORTH CHICAGO, IL – November 18, 2025 — AbbVie announced that the U.S. Food and Drug Administration (FDA) has...
AstraZeneca–Sun Pharma Join Forces to Expand Hyperkalaemia Treatment Access in India
Dateline – November 17, 2025 | Bengaluru, India In a significant development for India’s pharmaceutical ecosystem, AstraZeneca Pharma India...
Novo Nordisk Reshapes Leadership Structure Following EGM Vote
Dateline: November 14, 2025 — Bagsværd, DenmarkNovo Nordisk A/S announced a series of major Board of Directors changes following...
Lupin Debuts CGT-Exclusive Risperidone LAI in U.S. Market
Dateline: November 14, 2025 — Mumbai, India / Baltimore, MarylandLupin has launched its Risperidone Long-Acting Injectable (LAI) in the...
Milvexian Phase 3 ACS Trial Discontinued After Interim Review
Dateline: November 17, 2025 — Princeton, N.J.In a significant development for anticoagulant therapy, Milvexian (also known as Librexia) —...
Pharma Supply Chains Drive $451B Global Courier Boom
Dublin, November 10, 2025 — A new Research and Markets report forecasts the global B2B Courier, Express, and Parcels...
FDA Clears CAPLYTA® as New Adjunctive Therapy for Depression
Titusville, New Jersey – November 6, 2025 – Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and...
FDA Accepts Achieve Life Sciences’ Cytisinicline NDA for Smoking and Vaping Cessation
Seattle and Vancouver, November 6, 2025 : Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company, announced...